Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Agnes Gasiorek, Arne Heydorn, Sanaz Gabery, Julie Hjerpsted, Katrine Kirkeby, Thomas Kruse, Signe B Petersen, Søren Toubro, Andreas Vegge, Cassandra Key
Topics & Concepts
TolerabilityPharmacodynamicsPharmacokineticsPlaceboMedicinePharmacologyAgonistDouble blindAmylinClinical trialInternal medicineReceptorAdverse effectAlternative medicinePathologyInsulinIsletDiabetes Treatment and ManagementRegulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases